13
Mar

Bristol-Myers Squibb is finally in line for FDA approval for its once-rejected hepatitis C daclatasvir, angling to take third place among companies with next-generation cures for the virus.

…read more

Source: Bristol-Myers heads back to the FDA with its long-delayed hep C drug

    

0 No comments